The researchers are going to find out more effective to use an experimental compound AZD1775, developed by AstraZeneca, in combination with chemotherapy before surgery or with chemotherapy and radiation therapy after surgery.
Test phase 1 determines whether it is safe to combine AZD1775 with cisplatin chemotherapy before surgery and after in patients with head and neck cancer, and what dose is best. AZD1775 acts as a potent inhibitor of WEE1, a protein which regulates cell cycle. In preclinical studies, scientists have shown that it increases the effectiveness of chemotherapy with cisplatin and radiotherapy.
The study, coordinated by the Research Center of Cancer at the University of Birmingham, taking two groups of 21 patients participated. The first group receives 177 AZD with chemotherapy before surgery, and the second - AZD1775 in addition to chemotherapy or radiation therapy after surgery.
The standard treatment for head and neck cancer - chemotherapy with cisplatin and radiation therapy. Although this treatment is the most effective option for patients, the survival rate is still low, and treatment often has an adverse effect on the quality of life of survivors.
"Many patients are diagnosed with head and neck cancer are at high risk of recurrence after surgery, so it is necessary to find new ways to treat the disease - said Professor Hisham mechanical, principal investigator. - We hope that the combination of this drug with chemotherapy becomes more effective therapy, helping more people survive and improve quality of life after treatment. "
The researchers hope that the study will bring clinical benefit to patients aged 18 to 70 years old with throat cancer and larynx and oral cavity, which is to surgery.
"We welcome the opportunity to try a new drug. This allows us to combine the combination therapy using drugs that are still under development. We hope that this drug will improve the treatment of patients with head and neck cancer, "- says Dr. Ian Walker, director of clinical research.